

1

# Simvastatin therapy in different subtypes of hypercholesterolemia – a physiologically based modelling approach

Florian Bartsch<sup>1</sup>, Jan Grzegorzewski<sup>1</sup>, Helena Leal Pujol<sup>1</sup>, Hans-Michael Tautenhahn<sup>2</sup> and Matthias König<sup>1\*</sup>

<sup>1</sup>*Institute for Theoretical Biology, Humboldt University, Berlin, Germany*

<sup>2</sup>*Experimental Transplantation Surgery, Department of General, Visceral and Vascular Surgery, Jena University Hospital, Jena, Germany*

Correspondence\*:

Matthias König

konigmatt@gmail.com

## 2 ABSTRACT

Hypercholesterolemia is a multifaceted plasma lipid disorder with heterogeneous causes including lifestyle and genetic factors. A key feature of hypercholesterolemia is elevated plasma levels of low-density lipoprotein cholesterol (LDL-C). Several genetic variants have been reported to be associated with hypercholesterolemia, known as familial hypercholesterolemia (FH). Important variants affect the LDL receptor (LDLR), which mediates the uptake of LDL-C from the plasma, apolipoprotein B (APOB), which is involved in the binding of LDL-C to the LDLR, and proprotein convertase subtilisin/kexin type 9 (PCSK9), which modulates the degradation of the LDLR. A typical treatment for hypercholesterolemia is statin medication, with simvastatin being one of the most commonly prescribed statins. In this work, the LDL-C lowering therapy with simvastatin in hypercholesterolemia was investigated using a computational modeling approach. A physiologically based pharmacokinetic model of simvastatin integrated with a pharmacodynamic model of plasma LDL-C (PBPK/PD) was developed based on extensive data curation. A key component of the model is LDL-C turnover by the liver, consisting of: hepatic cholesterol synthesis with the key enzymes HMG-CoA reductase and HMG-CoA synthase; cholesterol export from the liver as VLDL-C; de novo synthesis of LDLR; transport of LDLR to the membrane; binding of LDL-C by LDLR via APOB; endocytosis of the LDLR-LDL-C complex; recycling of LDLR from the complex. The model was applied to study the effects of simvastatin therapy in hypercholesterolemia due to different causes in the LDLR pathway corresponding to different subtypes of hypercholesterolemia. Model predictions of LDL-C lowering therapy were validated with independent clinical data sets. Key findings are: (i) hepatic LDLR turnover is highly heterogeneous among FH classes; (ii) despite this heterogeneity, simvastatin therapy results in a consistent reduction in plasma LDL-C regardless of class; and (iii) simvastatin therapy shows a dose-dependent reduction in LDL-C. Our model suggests that the underlying cause of hypercholesterolemia does not influence simvastatin therapy. Furthermore, our model supports the treatment strategy of stepwise dose adjustment to achieve target LDL-C levels. Both the model and the database are freely available for reuse.

Keywords: simvastatin, hypercholesterolemia, LDL-cholesterol, LDL-receptor, physiologically based pharmacokinetic model, pharmacokinetics, pharmacodynamics, PK/PD

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## INTRODUCTION

Cholesterol is one of the most important and highly decorated molecules in biology (Brown et al., 1986). It is a critical structural component of cell membranes (Luo et al., 2019) and a precursor for a variety of important biomolecules such as bile acids, vitamin D or steroids (Cornforth and Popjaák, 1958). Cholesterol is a highly lipophilic compound and is transported in plasma by lipoproteins such as HDL (high density lipoprotein), LDL (low density lipoprotein), and VLDL (very low density lipoprotein).

The liver is the major site of cholesterol synthesis, clearance, and export into the plasma via VLDL cholesterol. 70% of the clearance of plasma LDL-C is mediated by LDL receptors on the membrane surface of hepatocytes (Gidding et al., 2015). Hepatic cholesterol levels can be increased by dietary cholesterol intake, uptake from plasma LDL-C, or hepatic *de novo* synthesis, and decreased by export to plasma, conversion to bile acids, or fecal excretion (Luo et al., 2019). The LDLR life cycle in the liver is tightly regulated by several key processes. These are (i) *de novo* synthesis of LDLR; (ii) transport of LDLR to the membrane; (iii) binding of extracellular LDL-C to membrane-bound LDLR via apolipoprotein B (APOB); (iv) endocytosis of the LDLR-LDL-C complex; and (v) recycling of LDLR from the complex. LDLR production rates in the liver are controlled by cholesterol levels in hepatocytes via negative feedback (Gidding et al., 2015).

A common abnormality in whole-body cholesterol homeostasis is elevated plasma levels of total cholesterol in combination with elevated LDL-C, known as hypercholesterolemia (Ibrahim et al., 2020). Hypercholesterolemia is associated with an increased risk for atherosclerosis, which can lead to cardio-, cerebro-, and peripheral morbidity and mortality (Christians et al., 1998). Cholesterol levels have become an important indicator of increased risk for cardiovascular disease (CVD) (Backer, 2003).

The main treatment for hypercholesterolemia is lifestyle changes such as lipid-lowering diets or lipid-lowering medications (Ibrahim et al., 2020). The most prominent medications are statins, which account for 95.8% of prescribed lipid-lowering medications in 2019 (Cheema et al., 2022). Statins can be used as lipid-lowering drugs because of their ability to inhibit the enzyme HMG-Coenzyme-A reductase (HMG-CoA reductase). This enzyme catalyzes the conversion of HMG-CoA to cholesterol, which is one of the major rate-limiting steps in cholesterol biosynthesis (Corsini et al., 1995). The resulting decrease in *de novo* cholesterol biosynthesis and hepatic cholesterol concentration leads to an upregulation of LDLR expression. As a consequence, the clearance of LDL-C from plasma by LDLR-mediated uptake into the liver increases, leading to a decrease in plasma LDL-C and total cholesterol concentrations (Magot et al., 1991).

Simvastatin is one of the most popular and widely used statins. In 2011-2012, 23.2% of adults aged 40 and over in the United States used simvastatin as a cholesterol-lowering medication (Gu, 2014). Simvastatin itself is a prodrug that must be activated in the liver by esterases to the main active metabolite, simvastatin acid. Both simvastatin and simvastatin acid are metabolized by cytochrome P450 3A (CYP3A4) in the small intestine and liver to other simvastatin metabolites that have less inhibitory activity than simvastatin acid. Simvastatin is a nonpolar and highly lipophilic compound capable of passive diffusion across biomembranes. After metabolism, the metabolites gain polarity and are subject to specific transporters (e.g., the hepatic influx of simvastatin acid is mediated by the OATP1B1 transporter) (Jiang et al., 2017). The rapid first-pass metabolism and hydrophilicity of simvastatin result in a bioavailability of only 5% (Mauro, 1993). These effects lead to accumulation of simvastatin acid and other active metabolites in the liver where they competitively inhibit HMG-CoA reductase (Germershausen et al., 1989). Simvastatin undergoes

71 enterohepatic circulation and is excreted as a variety of different simvastatin metabolites predominantly in  
72 the feces.

73 Hypercholesterolemia is a multifaceted disease with heterogeneous causes. These include mainly genetic  
74 and lifestyle factors (Ibrahim et al., 2020). Genetic factors typically lead to familial hypercholesterolemia  
75 (FH), which describes elevated plasma LDL cholesterol levels due to genetic disorders affecting the function  
76 of LDL-R, apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 (PCSK9) (Di Taranto  
77 et al., 2020). The different genetic variants can be classified as loss of function of LDLR or loss of binding  
78 capacity of LDLR to APOB on LDL-C particles (Di Taranto et al., 2020). FH can be classified into six  
79 classes (Gidding et al., 2015; Hobbs et al., 1992; Defesche et al., 2017):

- 80 • Class 1: LDLR or precursors are not synthesized.
- 81 • Class 2: LDLR is not properly transported from the endoplasmic reticulum to the Golgi apparatus for  
82 expression on the cell surface.
- 83 • Class 3: LDLR does not properly bind LDL because of a defect in either APOB-100 or in LDLR.
- 84 • Class 4: LDLR bound to LDL-C does not properly cluster in clathrin-coated pits for receptor-mediated  
85 endocytosis.
- 86 • Class 5: LDLR is not recycled back to the cell surface and is rapidly degraded.
- 87 • Class 6: LDLR is not initially transported to the basolateral membrane.

88 All classes result in reduced LDL-C uptake from plasma but have different underlying causes in the  
89 LDLR lifecycle (binding, uptake, recycling, synthesis, activity). These six classes are grouped into two  
90 main categories: (i) receptor-negative mutations, which result in no LDLR synthesis or the synthesis of a  
91 non-functional LDLR, and (ii) receptor-defective mutations, which result in the synthesis of a less effective  
92 LDLR (Defesche et al., 2017). In contrast to the six classes of FH, mutations in PCSK9 do not result in  
93 loss of function of proteins involved in LDLR expression, but in gain of function of proteins involved in  
94 LDLR degradation (Di Taranto et al., 2020).

95 An open question is how the different classes of FH affect lipid-lowering therapy with statins. A  
96 better understanding of simvastatin therapy and whether and how different treatment regimens work in  
97 the different classes may allow a more personalized approach to cholesterol-lowering therapy based on  
98 subgroup stratification. Because of the complex regulation of cholesterol synthesis and homeostasis and  
99 the pharmacokinetics and metabolism of simvastatin, this question has been difficult to answer. In addition,  
100 the correct dosage of simvastatin is a major challenge, as too low concentrations result in ineffectiveness  
101 (no or insufficient reduction in LDL-C) and too high concentrations result in possible side effects such  
102 as hypertension and muscle damage. It is unclear which dosing strategy should be used in which class.  
103 Computational modeling can be used as an important method to study such complex systems *in silico*.

104 Computational models of simvastatin (Moon and Smith, 2002; Ogungbenro et al., 2019; Tsamandouras  
105 et al., 2014, 2015; Kim et al., 2011; Methaneethorn et al., 2014; Lohitnavy et al., 2015; Kim et al., 2011;  
106 Wojtyniak et al., 2021), cholesterol (Paalvast et al., 2015; Wrona et al., 2015), and models of the effect  
107 of simvastatin on cholesterol levels (Kim et al., 2011) have been developed. Most of these studies used  
108 small patient cohorts for model development (mostly a single clinical trial) and lack validation with  
109 independent data sets. These models lack general applicability. Modeling approaches such as network  
110 analysis (Moon and Smith, 2002; Wojtyniak et al., 2021) or population pharmacokinetic models using  
111 mostly one-compartment models (Kim et al., 2011; Ogungbenro et al., 2019; Tsamandouras et al., 2014,  
112 2015; Methaneethorn et al., 2014) for simvastatin work well to describe a given data set, but they often

lack general interpretability because they do not explicitly represent physiology. They often include only simvastatin and sometimes simvastatin acid, ignoring other important active metabolites that contribute to the lipid-lowering effect of simvastatin. Such reduced models do not take into account how physiological changes, such as anthropometric factors, affect simvastatin therapy. One study used a large data set for model building and validation and examined the effect of simvastatin in combination with various drug-drug and drug-gene interactions (Wojtyniak et al., 2021). Importantly, different FH classes in relation to simvastatin therapy are not investigated in any of the existing models.

The aim of this work was to develop a physiologically based model of simvastatin and cholesterol to study LDL-C lowering therapy with simvastatin in different FH classes. Such a model can help to better understand the quantitative and qualitative effects of simvastatin treatment and its efficacy in patients with elevated plasma cholesterol. In addition, this model can be used to answer the open question of whether genetic screening could be beneficial for personalized simvastatin therapy, e.g. to adjust dosing protocols according to individual physiology and genetics.

## MATERIALS AND METHODS

### Data curation

A database of simvastatin pharmacokinetics and LDL-C pharmacodynamics in simvastatin therapy was established for model development and validation (see Tab. 1). The data set consists of concentration-time curves and pharmacokinetic parameters for simvastatin and its metabolites simvastatin acid, active and total HMG-CoA reductase inhibitors. The pharmacodynamic data set consists of time courses of plasma LDL-C concentration during simvastatin therapy.

Inclusion criteria for simvastatin studies were that the studies reported pharmacokinetics and/or concentration-time curves of simvastatin and its metabolites after single or multiple doses of simvastatin. Priority was given to studies reporting data under control conditions (healthy subjects without the intervention of other drugs). Inclusion criteria for cholesterol studies were that the studies reported plasma lipid concentrations or changes (at least for LDL-C) after single or multiple doses of simvastatin. For inclusion, studies had to report baseline concentrations before treatment. The data are accompanied by metadata about the subjects and groups studied (e.g., type of atherosclerosis) and the intervention used (e.g., dose and route of simvastatin administration). All data have been curated using an established curation pipeline (Grzegorzewski et al., 2022) and are available via the PK-DB pharmacokinetics database (<https://pk-db.com>) (Grzegorzewski et al., 2021).

### Computational model

A physiologically based PK/PD model was developed to predict simvastatin pharmacokinetics and cholesterol pharmacodynamics. The model is available in the Systems Biology Markup Language (SBML) (Hucka et al., 2019; Keating et al., 2020) under a CC-BY 4.0 license from <https://github.com/matthiaskoenig/simvastatin-model>. This paper used version 0.9.1 of the model (König and Bartsch, 2023). The model was developed using sbmlutils (König, 2022), simulated using sbmlsim (König, 2021) with libroadrunner (Somogyi et al., 2015; Welsh et al., 2023) as the high performance simulator, and visualized using cy3sbml (König et al., 2012).



## 150 **Model parameterization**

151 For model calibration, literature values were used for physiological and kinetic parameters such as  
152 Michaelis-Menten constants, inhibition constants, reference concentration values, blood flows and tissue  
153 volumes (see Tab. S1). The remaining model parameters were fitted by minimizing the residuals between  
154 the concentration-time curves from the curated data and the model predictions. The subset of data used for  
155 parameter fitting is listed in Tab. 1. All single-dose simvastatin studies were used for parameter fitting, with  
156 the exception of Keskitalo2008 (Keskitalo et al., 2008), which was excluded from parameter fitting due to  
157 genetic variants. The optimization problem was formulated as a nonlinear, bounded-variable least-squares  
158 problem and solved using SciPy's least-squares method to minimize residuals between model predictions  
159 and data points (Virtanen et al., 2020). A total of 17 model parameters related to simvastatin were fitted  
160 (see Tab. S2).

## 161 **Familial hypercholesterolemia subtypes**

162 To study the effect of different subtypes of familial hypercholesterolemia on plasma LDL-C levels and  
163 hepatic cholesterol metabolism, model parameters have been added that allow the degree of functional  
164 change within different steps of the LDLR pathway to be scanned. These have a default value of 1 and can  
165 be scanned to simulate different classes of FH. These scaling parameters are listed in Tab. S3. FH classes 1,  
166 3, 4, and 5 are implemented with a single scaling parameter. Both class 2 and class 6 affect the membrane  
167 transport of LDLR: class 2 affects transport from the ER to the Golgi apparatus for cell surface expression,  
168 and class 6 affects the initial transport of LDLR to the basolateral membrane. Membrane transport of  
169 LDLR was modeled by a single overall reaction that combined these steps. Consequently, class 2 and 6  
170 could not be distinguished in the model and were described by a single parameter. To describe the effects  
171 of mutations in PCSK9, an additional scaling parameter affecting the degradation of LDLR was added. All  
172 parameters for the FH classes are set to 1.0 in the model reference state corresponding to 3 mM plasma  
173 LDL-C. Parameters have been varied in [0.01, 100] corresponding to different degrees of function.

## 174 **Baseline LDL-C values**

175 The model was calibrated to a baseline reference plasma LDL-C of 3 mM. For calibration, LDL-C  
176 consumption was adjusted using the calibration curve in Fig. S1. To establish specific baseline plasma  
177 LDL-C concentrations in the different hypercholesterolemic classes, each FH parameter was adjusted using  
178 the calibration curves in Fig. S2. To determine these curves, each FH parameter was scanned in the range  
179 [10E-3, 10E3] and a time course simulation was performed over 52 weeks until steady-state LDL-C values  
180 were reached. The values were interpolated and the interpolation curve was used to determine the change  
181 in FH parameter for a given LDL-C value.

## **RESULTS**

182 In this work, we developed a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model  
183 of simvastatin (SV) and its pharmacodynamic effect on plasma LDL-C. The model was applied to study  
184 the LDL-C-lowering effect of simvastatin therapy in different subtypes of hypercholesterolemia.

## **Database on the pharmacokinetics and pharmacodynamics of simvastatin**

A large pharmacokinetic database of simvastatin and its metabolites (Tab. 1) combined with a pharmacodynamic database of the LDL-C lowering effect of simvastatin therapy (Tab. 2) was established for the development and evaluation of the model.

The pharmacokinetic database consists of 27 studies reporting simvastatin time courses or pharmacokinetic parameters. Of the studies, 23 report simvastatin (SV) time courses after single oral administration (Backman et al., 2000; Chung et al., 2006; Gehin et al., 2015; Jacobson, 2004; Jiang et al., 2017; Kantola et al., 1998; Keskitalo et al., 2008, 2009; Kim et al., 2019; Kyrklund et al., 2000; Lilja et al., 2000, 2004; Lohitnavy et al., 2004; Marino et al., 2000; Mousa et al., 2000; Neuvonen et al., 1998; Pasanen et al., 2006; Pentikainen et al., 1992; Tubic-Grozdanis et al., 2008; Ucar et al., 2004; Zhou et al., 2013). In addition, 7 studies report time courses after multiple oral administrations of simvastatin (Bergman et al., 2004; Hsyu et al., 2001; Jacobson, 2004; Nishio et al., 2005; Simard et al., 2001; Zhi et al., 2003; Ziviani et al., 2001). A single study reported both, time courses after single and multiple doses of simvastatin (Jacobson, 2004). 24 studies reported time courses for SV, 19 for simvastatin acid (SVA), 3 for SV + SVA, 5 for active HMG-CoA reductase inhibitors, and 5 for total HMG-CoA reductase inhibitors.

The pharmacodynamics data set consists of 18 studies that reported on plasma LDL-C or changes in plasma LDL-C with simvastatin therapy (see Tab. 2) (Crouse 3rd et al., 1999; Davidson et al., 1997; Geiss et al., 2002; Isaacssohn et al., 2003; Jones et al., 1998; Keech et al., 1994; Kosoglou et al., 2002; Loria et al., 1994; Li et al., 2003; Mølgaard et al., 1988; Mol et al., 1986, 1988; Ntanios et al., 1999; Nishio et al., 2005; Owens et al., 1991; Pietro et al., 1989; Recto et al., 2000; Tuomilehto et al., 1994; Walker et al., 1990). Study duration was heterogeneous, ranging from 2 weeks to 3 years, with one study reporting plasma LDL-C after a single dose application (Loria et al., 1994). Most studies did not provide sufficient information on FH phenotypes in the study cohort. Some studies included subjects with polygenic, heterozygous, homozygous, mixed, or type 2 hypercholesterolemia. All study cohorts consisted of patients with elevated plasma LDL-C levels, except for Loria1993 (Loria et al., 1994).

To our knowledge, this is the first large freely available data set of pharmacokinetic and pharmacodynamic data for simvastatin with all data accessible from the pharmacokinetic database (PK-DB) (Grzegorzewski et al., 2021).

## **PBPK/PD model of simvastatin**

A physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model of simvastatin (SV) and its pharmacodynamic effect on plasma LDL-C was developed to study SV therapy in different classes of hypercholesterolemia (Fig. 1). The whole-body model (Fig. 1A) consists of the liver, kidney, gastrointestinal tract, lungs, and the rest compartment. Organs of minor relevance are not explicitly modeled and are lumped into the rest compartment. Organs are coupled via the systemic circulation. SV can be administered orally (PO).

In the liver model (Fig. 1B), SV is converted to SVM by CYP3A. Alternatively, esterases catalyze the reaction of SV to SVA with subsequent conversion to SVM by CYP3A4. This is the main activation process of simvastatin. SV, SVA, and SVM can be exchanged between the liver and the circulation. SVM accounts for all simvastatin metabolites after metabolism by either CYP3A4 or esterases. SVM can be transported via enterohepatic circulation (EHC) from the liver into the gastrointestinal tract.

The intestinal model (Fig. 1C) describes the dissolution and absorption of SV, absorption of SV, and first pass metabolism of SV to SVM via CYP3A4 in the enterocytes of the intestinal wall. Only a fraction of

SVM that reaches the intestine via the enterohepatic circulation (EHC) is absorbed, with the remainder excreted in the feces, whereas SV can be completely absorbed.

The kidney model (Fig. 1D) describes the urinary excretion of SVM. There is no renal clearance of SV and SVA.

To study the effects of simvastatin therapy, the simvastatin pharmacokinetic model was extended to include the major processes affecting plasma LDL-C levels. The liver model (Fig. 1B) includes the major processes relevant to hepatic cholesterol homeostasis, including dietary cholesterol uptake, fecal cholesterol loss, a shortened cholesterol biosynthetic pathway, and uptake of cholesterol from plasma as LDL-C. Cholesterol can be exported from the liver as VLDL-C. Hepatic cholesterol synthesis is modeled via the precursor reaction from acetyl-CoA to HMG-CoA mediated by HMG-CoA synthase and the reaction from HMG-CoA to cholesterol mediated by HMG-CoA reductase. SVA and SVM are competitive inhibitors of HMG-CoA reductase. An important regulatory mechanism in the model is the adjustment of protein levels of HMG-CoA synthase, HMG-CoA reductase and LDLR by hepatic cholesterol levels. As cholesterol levels decrease, protein synthesis rates increase and protein degradation rates decrease for these proteins, resulting in an increase in these key enzymes of cholesterol synthesis.

A key component of the model is the hepatic LDL receptor (LDLR) pathway consisting of (1) LDLR synthesis; (2) transport of LDLR to the membrane; (3) binding of LDL-C to LDLR; (4) internalization of the LDLR-LDL-C complex; (5) recycling of LDLR; and (P) degradation of LDLR. The effect of altering these steps was systematically evaluated to implement different subtypes of familial hypercholesterolemia.

To our knowledge, this is the first freely available, reproducible, and reusable PBPK/PD model of simvastatin pharmacokinetics and pharmacodynamics with the model available in SBML from <https://github.com/matthiaskoenig/simvastatin-model>.

## **Simvastatin time courses**

The performance of the simvastatin PBPK model was evaluated by comparing model predictions of the time courses of simvastatin and its metabolites with data from the curated studies. Time course data after a single dose of simvastatin were used as the training data set, and data after multiple doses of simvastatin were used as an independent validation data set (see Tab. 1). Model predictions for simvastatin, simvastatin acid, total simvastatin inhibitors, active simvastatin inhibitors and simvastatin plus simvastatin acid (see Fig. 2) were in good agreement with the training data from 21 studies (Backman et al., 2000; Chung et al., 2006; Gehin et al., 2015; Jacobson, 2004; Jiang et al., 2017; Kantola et al., 1998; Keskitalo et al., 2008, 2009; Kim et al., 2019; Kyrklund et al., 2000; Lilja et al., 2000, 2004; Lohitnavy et al., 2004; Marino et al., 2000; Mousa et al., 2000; Neuvonen et al., 1998; Pasanen et al., 2006; Pentikainen et al., 1992; Tubic-Grozdanis et al., 2008; Ucar et al., 2004; Zhou et al., 2013). Similar good performance of the model was observed on the validation data set consisting of 7 studies with good agreement between model predictions and data (see Fig. 2) (Bergman et al., 2004; Hsyu et al., 2001; Jacobson, 2004; Nishio et al., 2005; Simard et al., 2001; Zhi et al., 2003; Ziviani et al., 2001). The resulting simvastatin PBPK model accurately predicts plasma concentrations of simvastatin and its metabolites under single and multiple applications of simvastatin.

## **Simvastatin therapy in hypercholesterolemia subtypes**

The PBPK/PD model was calibrated to a baseline LDL-C concentration of 3 mM. To study the effect of modifying key steps of the LDLR pathway, the FH parameters for the respective familial

hypercholesterolemia subtypes were varied by a factor of 10 at time 0 in the direction of increasing LDL-C levels. Time course simulations were performed for 52 weeks of no therapy followed by either simvastatin therapy with 20 mg simvastatin daily or no therapy for 52 weeks (Fig. 4). A zoom of the last week of simvastatin treatment is shown in Fig. S3. As a control in the no mutation simulation, no changes in the LDLR pathway were made under the same simvastatin dosing regimen.

Alterations in (1) LDLR synthesis (FH class 1), (2) transport of LDLR to the membrane (FH class 2 & 6), (3) binding of LDL-C to LDLR (FH class 3), (4) internalization of the LDLR-LDL-C complex (FH class 4), (5) recycling of LDLR (FH class 5), and (P) degradation of LDLR (PSCK9 mutation) all lead to hypercholesterolemia, but to different degrees (Fig. 4C). It takes 15-25 weeks for each FH class to reach a new LDL-C steady state after the change in the LDL-R pathway.

Simvastatin therapy reduces LDL-C in all subtypes by 2-4 mM. It takes approximately 20 weeks for each class to reach new LDL-C steady states after initiation of simvastatin therapy. Large daily fluctuations in metabolites and rates are observed during simvastatin therapy (Fig. S3). Both SV and SVA vary throughout the day with peaks around 2-3 hours after dosing (see also Fig. 2 and Fig. 3), with concentrations declining to almost zero after 24 hours due to the relatively fast half-life of simvastatin. As a consequence of the diurnal variation of HMG-CoA reductase inhibitors, the rate of hepatic cholesterol synthesis, hepatic cholesterol levels and the rate of VLDL-C export show large variations (Fig. 4D and H).

The different subtypes of hypercholesterolemia show a similar effect on LDL-C levels, consisting of an increase in LDL-C followed by a reduction with simvastatin therapy. Despite these similarities, large differences can be observed in the LDL-R pathway (Fig. 4E-I).

To study the effect of the degree of change in the hypercholesterolemia subtypes, the FH parameters were varied in [0.01, 100] (Fig. 5). Simulations were analogous to Fig. 4, i.e. 52 weeks of no therapy followed by either simvastatin therapy with 20 mg simvastatin daily or no therapy for 52 weeks. Values represent the mean  $\pm$  SD concentration of the last day.

Plasma LDL-C levels show a sigmoidal dependence on the FH parameter, i.e. changes in key steps of the LDLR pathway are monotonically related to changes in plasma LDL-C levels. Plasma LDL-C does not vary much during the day. Interestingly, hepatic cholesterol behaves inversely to plasma LDL-C. High hepatic cholesterol concentrations result in low plasma LDL-C concentrations with large variations in hepatic cholesterol, and low hepatic cholesterol concentrations result in high plasma LDL-C concentrations with small variations over a day.

The different subtypes of hypercholesterolemia show a similar effect on LDL-C levels, consisting of an increase in LDL-C followed by a reduction with simvastatin therapy. Despite these similarities, large differences can be observed in the LDL-R pathway (Fig. 5E-I).

## **Prediction of LDL-C reduction with simvastatin therapy**

We then used the developed model to predict the reduction in plasma LDL-C with simvastatin therapy (Fig. 6) for data from (Crouse 3rd et al., 1999; Davidson et al., 1997; Geiss et al., 2002; Isaacsohn et al., 2003; Jones et al., 1998; Keech et al., 1994; Kosoglou et al., 2002; Loria et al., 1994; Li et al., 2003; Mølgaard et al., 1988; Mol et al., 1986, 1988; Ntanios et al., 1999; Nishio et al., 2005; Owens et al., 1991; Pietro et al., 1989; Recto et al., 2000; Saito et al., 1991; Tuomilehto et al., 1994; Walker et al., 1990). Simvastatin dose, dosing interval, and duration of therapy were used to simulate each study (see Tab. 2). Baseline LDL-C levels were adjusted individually for each simulation to match the data. For each study, all



hypercholesterolemia subtypes were simulated and the mean and range of predictions were compared with the data.

Simvastatin therapy leads to a reduction in plasma LDL-C levels within a few weeks of treatment initiation. The predicted LDL-C time courses were generally in good agreement with the data over a wide range of simvastatin doses and dosing protocols. The model predictions are analyzed more systematically in Fig. 7 and Fig. S4. The predicted data are in good agreement with the observed data, especially for absolute reductions larger than -2 mM (Fig. 7A) and for relative reductions larger than -30% (Fig. 7D).

To examine the time and dose dependence of LDL-C reduction, the data were compared to a reference simulation of the model with a baseline LDL-C of 5.9 mM. The simulations were performed for all hypercholesterolemic subtypes and the mean and range are shown for absolute LDL-C reductions in Fig. 7B and for relative LDL-C reductions from baseline in Fig. 7E. A clear dose-response relationship can be observed, with increasing simvastatin dose leading to increasing LDL-C reduction. After 15-20 weeks of therapy, the model reaches maximum LDL-C reductions. Finally, the corresponding time-dependent residuals were calculated for absolute LDL-C reductions in Fig. 7C and relative LDL-C reductions from baseline in Fig. 7F.

## **Effect of simvastatin dose and hypercholesterolemia subtype on LDL-C reduction**

As shown in Fig. 7, there is a clear dose-dependent effect in LDL-C reduction with simvastatin therapy. To systematically study this effect in different subtypes of hypercholesterolemia, simvastatin was administered at daily doses of 2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg, 80 mg, and 160 mg. The resulting plasma LDL-C and absolute and relative reductions by subtype and magnitude of change are shown in Fig. 8. Simvastatin is able to reduce plasma LDL-C in each subtype (Fig. 8B). The absolute reduction (Fig. 8C) depends on the plasma LDL-C level, with higher pretreatment LDL-C levels resulting in greater absolute reductions. With increasing simvastatin dose, the absolute reductions and relative inductions increase. An important finding is that similar relative reductions are achieved at a given dose regardless of the underlying subtype of familial hypercholesterolemia and the extent of alteration in the LDLR pathways (Fig. 8D).

## **DISCUSSION**

In this work, a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model of simvastatin was developed and applied to study the LDL-C-lowering effect of simvastatin therapy in different subtypes of hypercholesterolemia.

The main findings of this paper are: (i) Hepatic LDLR turnover is highly heterogeneous among FH classes; despite the very similar effect of the different alterations on plasma LDL-C, i.e. increased LDL-C levels that could be reduced with simvastatin therapy, large differences in LDLR pathways and hepatic metabolites were observed among the different classes.

(ii) Despite this heterogeneity, simvastatin therapy results in a consistent lowering of plasma LDL-C regardless of class; the relative reduction for a given simvastatin dose is very similar regardless of the underlying cause. Our model suggests that inhibition of HMG-CoA reductase and cholesterol synthesis is an effective way to reduce elevated plasma LDL-C for all subtypes studied here. Our model suggests that the underlying cause of hypercholesterolemia in the FH classes does not affect simvastatin therapy. To answer the open question of whether genetic screening could be useful for personalized simvastatin therapy, e.g. to adjust dosing protocols according to individual physiology and genetics, our model says no.



348 Testing could provide valuable information for understanding the underlying individual pathophysiology of  
349 hypercholesterolemia, but will not add value to simvastatin therapy.

350 (iii) Simvastatin therapy shows a dose-dependent reduction in LDL-C. Our model supports the treatment  
351 strategy of stepwise dose adjustment to achieve target LDL-C levels. Both the model and the database are  
352 freely available for reuse.

353 The model spans time scales from very fast hepatic response kinetics to daily simvastatin therapy of  
354 up to years. The model incorporates slow adaptation processes that require 20-30 weeks after mutations  
355 in the LDLR pathway to reach steady state LDL-C levels. These slow timescales are also evident during  
356 simvastatin therapy, which requires a few weeks of daily dosing to achieve maximal reductions in  
357 plasma LDL-C. Daily peaks of HMG-CoA reductase inhibition are observed due to the rapid half-life of  
358 simvastatin, which reduces plasma concentrations to nearly zero after 24 hours. The short-term simvastatin  
359 pharmacokinetic model, coupled with a long-term cholesterol pharmacodynamic model, allows the effects  
360 of simvastatin to be studied in detail. Within the cholesterol model, we have been able to relate short-term  
361 inhibition of synthesis to long-term adjustments in protein levels. This allows us to predict and compare  
362 simvastatin-lowering therapy in patients with different FH types on a timescale of seconds to years. The  
363 model can discriminate between different FH subtypes and predict simvastatin efficacy and could effectively  
364 predict simvastatin doses, dosing intervals and duration required to achieve optimal simvastatin therapy.

365 During the last 20 years, various modeling approaches and software have been used to study different  
366 aspects of simvastatin pharmacokinetics (Moon and Smith, 2002; Ogungbenro et al., 2019; Tsamandouras  
367 et al., 2014, 2015; Kim et al., 2011; Methaneethorn et al., 2014; Lohitnavy et al., 2015; Kim et al., 2011;  
368 Wojtyniak et al., 2021), cholesterol metabolism (Paalvast et al., 2015; Wrona et al., 2015) and the effect  
369 of simvastatin on cholesterol levels (Kim et al., 2011). However, most of the work is difficult to validate  
370 or build upon due to the lack of accessibility of the models and software. Here, we provide an openly  
371 accessible, reproducible, and platform-independent whole-body model of simvastatin and LDL-C that  
372 facilitates reusability, extensibility, and comparability. The model was developed and validated on a large  
373 database of heterogeneous studies and is freely available in the open standard SBML (Keating et al., 2020).

374 The PBPK/PD model was able to accurately predict simvastatin pharmacokinetics and LDL-C reduction  
375 with simvastatin therapy. However, the model has several limitations. Most importantly, the model focused  
376 on the role of hepatic cholesterol synthesis and the LDLR pathway in plasma LDL-C. Because of the focus  
377 on the liver, the whole-body effect on cholesterol homeostasis was modeled only phenomenologically, e.g.,  
378 dietary cholesterol uptake via an average uptake rate, and the role of other organs and tissues in systemic  
379 cholesterol homeostasis was not modeled in detail but lumped into an overall cholesterol consumption.  
380 Inhibition of HMG-CoA reductase by simvastatin metabolites was considered only in the liver, the major  
381 site of cholesterol synthesis, but the enzyme is also inhibited in other tissues, leading to potential side  
382 effects. While the LDLR pathway was modeled in some detail, cholesterol synthesis was simplified to the  
383 key steps of acetyl-CoA to HMG-CoA via HMG-CoA synthase and from HMG-CoA to cholesterol via  
384 HMG-CoA reductase.

385 An additional limitation of the model evaluation was the lack of data on hepatic cholesterol metabolism.  
386 Additional data other than plasma LDL-C concentrations would be very helpful to validate and improve  
387 the model.

388 The focus of the model was on LDL-C, but other substances such as VLDL-C, HDL-C and triglycerides  
389 also play an important role in hypercholesterolemia. Our data set already includes all data for these

substances in simvastatin therapy, which were often reported together with LDL-C levels. Future work will extend the pharmacodynamic model to provide a broader view of changes in simvastatin therapy.

Importantly, we complement our open and accessible model with a large, open and accessible database of simvastatin pharmacokinetics and LDL-C pharmacodynamics in simvastatin therapy. The established database of simvastatin pharmacokinetics consists of pharmacokinetic studies with single or multiple doses of simvastatin in healthy patients. To our knowledge, no study has reported simvastatin pharmacokinetics in hypercholesterolemic patients. Therefore, it is unclear whether there is a systematic difference between simvastatin pharmacokinetics in healthy subjects and hypercholesterolemic patients.

Most of the reported data on the pharmacodynamics of simvastatin therapy, such as the reduction of plasma LDL-C, were poorly documented. This is consistent with our recent findings of poor quality pharmacokinetic data in the literature (Grzegorzewski et al., 2021, 2022). All pharmacodynamic studies reported baseline cholesterol levels, but data during and after simvastatin therapy were very heterogeneous. Some studies reported absolute changes in LDL-C, some relative changes, and some absolute plasma concentrations either with or without uncertainties such as standard deviation. The heterogeneity in reporting and the lack of complete data (concentrations, absolute changes, and relative changes) posed a major challenge for data integration. Additional information on the subjects was rarely and inconsistently reported (e.g. anthropometric information, diet). Most studies did not report the underlying cause of hypercholesterolemia.

Only a single study reported simvastatin pharmacokinetics and LDL-C pharmacodynamics (Loria et al., 1994). However, this study was limited to a single day and normocholesterolemic subjects. For model validation long-term studies measuring simvastatin pharmacokinetics and its LDL-C lowering effects in hypercholesterolemic patients would be a very valuable asset.

In this work, LDL-C lowering therapy with simvastatin in hypercholesterolemia was studied using a computational modeling approach. The main findings are: (i) hepatic LDLR turnover is highly heterogeneous among FH classes; (ii) despite this heterogeneity, simvastatin therapy results in a consistent lowering of plasma LDL-C independent of class; and (iii) simvastatin therapy shows a dose-dependent reduction in LDL-C. Our model suggests that the underlying cause of hypercholesterolemia in FH classes does not affect simvastatin therapy. Furthermore, our model supports the treatment strategy of stepwise dose adjustment to achieve target LDL-C levels. Both the model and the database are freely available for reuse.

## ACKNOWLEDGMENTS

FB, JG and MK are supported by the Federal Ministry of Education and Research (BMBF, Germany) within the research network Systems Medicine of the Liver (LiSyM, grant number 031L0054). FB and MK are supported by the German Research Foundation (DFG) within the Research Unit Programme FOR 5151 "QuaLiPerF (Quantifying Liver Perfusion-Function Relationship in Complex Resection - A Systems Medicine Approach)" by grant number 436883643. MK and HMT are supported by grant number 465194077 (Priority Programme SPP 2311, Subproject SimLivA). This work was supported by the BMBF-funded de.NBI Cloud within the German Network for Bioinformatics Infrastructure (de.NBI) (031A537B, 031A533A, 031A538A, 031A533B, 031A535A, 031A537C, 031A534A, 031A532B).

## AUTHOR CONTRIBUTIONS

428 FB and MK designed the study, developed the computational model, performed the analysis, and wrote the  
429 first draft of the manuscript. JG provided assistance with PK-DB (<https://pk-db.com>), data curation, and  
430 meta-analysis. All authors contributed to and critically revised the manuscript.

## DATA AVAILABILITY STATEMENT

431 The data sets analyzed in this study are available from PK-DB at <https://pk-db.com>.

## REFERENCES

- 432 Backer, D. (2003). European guidelines on cardiovascular disease prevention in clinical practice: Third  
433 Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical  
434 Practice (constituted by representatives of eight societies and by invited experts). *European Heart*  
435 *Journal* 24, 1601–1610. doi:10.1016/S0195-668X(03)00347-6
- 436 Backman, J. T., Kyrklund, C., Kivistö, K. T., Wang, J.-S., and Neuvonen, P. J. (2000). Plasma concentrations  
437 of active simvastatin acid are increased by gemfibrozil. *Clinical Pharmacology & Therapeutics* 68,  
438 122–129
- 439 Bergman, A. J., Murphy, G., Burke, J., Zhao, J. J., Valesky, R., Liu, L., et al. (2004). Simvastatin does  
440 not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. *The Journal of*  
441 *Clinical Pharmacology* 44, 1054–1062
- 442 Brown, M. S., Goldstein, J. L., et al. (1986). A receptor-mediated pathway for cholesterol homeostasis.  
443 *Science* 232, 34–47
- 444 Cheema, K. M., Dicks, E., Pearson, J., and Samani, N. J. (2022). Long-term trends in the epidemiology of  
445 cardiovascular diseases in the UK: insights from the british heart foundation statistical compendium.  
446 *Cardiovascular Research*
- 447 Christians, U., Jacobsen, W., and Floren, L. C. (1998). Metabolism and drug interactions of 3-hydroxy-3-  
448 methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically  
449 similar? *Pharmacology & Therapeutics* 80, 1 – 34. doi:[https://doi.org/10.1016/S0163-7258\(98\)00016-3](https://doi.org/10.1016/S0163-7258(98)00016-3)
- 450 Chung, E., Nafziger, A. N., Kazierad, D. J., and Bertino Jr, J. S. (2006). Comparison of midazolam and  
451 simvastatin as cytochrome P450 3A probes. *Clinical Pharmacology & Therapeutics* 79, 350–361
- 452 Cornforth, J. W. and Popjaák, G. (1958). Biosynthesis of cholesterol. *British Medical Bulletin* 14, 221–225.  
453 doi:10.1093/oxfordjournals.bmb.a069687
- 454 Corsini, A., Maggi, F. M., and Catapano, A. L. (1995). Pharmacology of competitive inhibitors of  
455 HMG-CoA reductase. *Pharmacological Research* 31, 9–27
- 456 Crouse 3rd, J., Frohlich, J., Ose, L., Mercuri, M., and Tobert, J. A. (1999). Effects of high doses of  
457 simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein AI. *The American*  
458 *journal of cardiology* 83, 1476–7
- 459 Davidson, M. H., Stein, E. A., Dujovne, C. A., Hunninghake, D. B., Weiss, S. R., Knopp, R. H., et al.  
460 (1997). The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. *The American journal*  
461 *of cardiology* 79, 38–42
- 462 Defesche, J. C., Gidding, S. S., Harada-Shiba, M., Hegele, R. A., Santos, R. D., and Wierzbicki, A. S.  
463 (2017). Familial hypercholesterolaemia. *Nature reviews Disease primers* 3, 1–20
- 464 Di Taranto, M. D., Giacobbe, C., and Fortunato, G. (2020). Familial hypercholesterolemia: A complex  
465 genetic disease with variable phenotypes. *European journal of medical genetics* 63, 103831

- 466 Gehin, M., Sidharta, P. N., Gnerre, C., Treiber, A., Halabi, A., and Dingemanse, J. (2015). Pharmacokinetic  
467 interactions between simvastatin and setipiprant, a CRTH2 antagonist. *European journal of clinical*  
468 *pharmacology* 71, 15–23
- 469 Geiss, H., Schwandt, P., and Parhofer, K. (2002). Influence of simvastatin on LDL-subtypes in patients  
470 with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed  
471 hyperlipoproteinemia. *Experimental and clinical endocrinology & diabetes* 110, 182–187
- 472 Germershausen, J. I., Hunt, V. M., Bostedor, R. G., Bailey, P. J., Karkas, J. D., and Alberts, A. W. (1989).  
473 Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo.  
474 *Biochemical and biophysical research communications* 158, 667–675
- 475 Gidding, S. S., Ann Champagne, M., de Ferranti, S. D., Defesche, J., Ito, M. K., Knowles, J. W., et al.  
476 (2015). The agenda for familial hypercholesterolemia: a scientific statement from the American Heart  
477 Association. *Circulation* 132, 2167–2192
- 478 Grzegorzewski, J., Bartsch, F., Köller, A., and König, M. (2022). Pharmacokinetics of caffeine: A  
479 systematic analysis of reported data for application in metabolic phenotyping and liver function testing.  
480 *Frontiers in Pharmacology* 12, 3772
- 481 Grzegorzewski, J., Brandhorst, J., Green, K., Eleftheriadou, D., Duport, Y., Barthorscht, F., et al. (2021).  
482 PK-DB: pharmacokinetics database for individualized and stratified computational modeling. *Nucleic*  
483 *acids research* 49, D1358–D1364. doi:10.1093/nar/gkaa990
- 484 Gu, Q. (2014). *Prescription cholesterol-lowering medication use in adults aged 40 and over: United States,*  
485 *2003-2012.* 2015 (US Department of Health and Human Services, Centers for Disease Control and ...)
- 486 Hobbs, H. H., Brown, M. S., and Goldstein, J. L. (1992). Molecular genetics of the LDL receptor gene in  
487 familial hypercholesterolemia. *Human mutation* 1, 445–466
- 488 Hsyu, P.-H., Schultz-Smith, M. D., Lillibridge, J. H., Lewis, R. H., and Kerr, B. M. (2001). Pharmacokinetic  
489 interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors  
490 atorvastatin and simvastatin. *Antimicrobial agents and chemotherapy* 45, 3445–3450
- 491 Hucka, M., Bergmann, F. T., Chaouiya, C., Dräger, A., Hoops, S., Keating, S. M., et al. (2019). The  
492 systems biology markup language (SBML): Language specification for Level 3 Version 2 core release 2.  
493 *Journal of Integrative Bioinformatics*
- 494 Ibrahim, M. A., Asuka, E., and Jialal, I. (2020). *Hypercholesterolemia* (StatPearls Publishing, Treasure  
495 Island (FL))
- 496 Isaacsohn, J., Hunninghake, D., Schrott, H., Dujovne, C. A., Knopp, R., Weiss, S. R., et al. (2003).  
497 Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. *Clinical*  
498 *Cardiology: An International Indexed and Peer-Reviewed Journal for Advances in the Treatment of*  
499 *Cardiovascular Disease* 26, 18–24
- 500 Jacobson, T. A. (2004). Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and  
501 atorvastatin when coadministered with cytochrome P450 inhibitors. *The American journal of cardiology*  
502 94, 1140–1146
- 503 Jiang, F., Choi, J.-Y., Lee, J.-H., Ryu, S., Park, Z.-W., Lee, J.-G., et al. (2017). The influences of SLCO1B1  
504 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition.  
505 *Pharmacogenomics* 18, 459–469. doi:10.2217/pgs-2016-0199. PMID: 28350522
- 506 Jones, P., Kafonek, S., Hunninghake, D., et al. (1998). Comparative dose efficacy study of atorvastatin  
507 versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the  
508 CURVES study). *The American journal of cardiology* 81, 582–587




- 509 Kantola, T., Kivistö, K. T., and Neuvonen, P. J. (1998). Erythromycin and verapamil considerably increase  
510 serum simvastatin and simvastatin acid concentrations. *Clinical Pharmacology & Therapeutics* 64,  
511 177–182
- 512 Keating, S. M., Waltemath, D., König, M., Zhang, F., Dräger, A., Chaouiya, C., et al. (2020). SBML Level  
513 3: an extensible format for the exchange and reuse of biological models. *Molecular systems biology* 16,  
514 e9110. doi:10.15252/msb.20199110
- 515 Keech, A., Collins, R., MacMahon, S., Armitage, J., Lawson, A., Wallendszus, K., et al. (1994). Three-year  
516 follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in  
517 preparation for a large mortality study. *European heart journal* 15, 255–269
- 518 Keskitalo, J. E., Kurkinen, K. J., Neuvonen, P. J., and Niemi, M. (2008). ABCB1 haplotypes differentially  
519 affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. *Clinical*  
520 *Pharmacology & Therapeutics* 84, 457–461
- 521 Keskitalo, J. E., Pasanen, M. K., Neuvonen, P. J., and Niemi, M. (2009). Different effects of the ABCG2 c.  
522 421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. *Pharmacogenomics*  
523 10, 1617–1624
- 524 Kim, J., Ahn, B.-J., Chae, H.-S., Han, S., Doh, K., Choi, J., et al. (2011). A population pharmacokinetic–  
525 pharmacodynamic model for simvastatin that predicts low-density lipoprotein-cholesterol reduction in  
526 patients with primary hyperlipidaemia. *Basic & clinical pharmacology & toxicology* 109, 156–163
- 527 Kim, J.-R., Jung, J. A., Kim, S., Huh, W., Ghim, J.-L., Shin, J.-G., et al. (2019). Effect of cilostazol on the  
528 pharmacokinetics of simvastatin in healthy subjects. *BioMed research international* 2019
- 529 König, M., Dräger, A., and Holzhütter, H.-G. (2012). CySBML: a Cytoscape plugin for SBML.  
530 *Bioinformatics* 28, 2402–2403
- 531 Kosoglou, T., Meyer, I., Veltri, E. P., Statkevich, P., Yang, B., Zhu, Y., et al. (2002). Pharmacodynamic  
532 interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. *British*  
533 *journal of clinical pharmacology* 54, 309–319
- 534 Kyrklund, C., Backman, J. T., Kivistö, K. T., Neuvonen, M., Laitila, J., and Neuvonen, P. J. (2000).  
535 Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. *Clinical Pharmacology*  
536 *& Therapeutics* 68, 592–597
- 537 [Dataset] König, M. (2021). sbmlsim: SBML simulation made easy. doi:10.5281/zenodo.5531088
- 538 [Dataset] König, M. (2022). sbmlutils: Python utilities for SBML. doi:10.5281/zenodo.7462781
- 539 [Dataset] König, M. and Bartsch, F. (2023). Simvastatin and cholesterol physiological based  
540 pharmacokinetics model (PBPK). doi:10.5281/zenodo.7540806
- 541 Li, J.-J., Chen, M.-Z., Chen, X., and Fang, C.-H. (2003). Rapid effects of simvastatin on lipid profile and  
542 c-reactive protein in patients with hypercholesterolemia. *Clinical Cardiology: An International Indexed*  
543 *and Peer-Reviewed Journal for Advances in the Treatment of Cardiovascular Disease* 26, 472–476
- 544 Lilja, J. J., Kivistö, K. T., and Neuvonen, P. J. (1998). Grapefruit juice—simvastatin interaction: Effect on  
545 serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. *Clinical*  
546 *Pharmacology & Therapeutics* 64, 477–483
- 547 Lilja, J. J., Kivistö, K. T., and Neuvonen, P. J. (2000). Duration of effect of grapefruit juice on the  
548 pharmacokinetics of the CYP3A4 substrate simvastatin. *Clinical Pharmacology & Therapeutics* 68,  
549 384–390
- 550 Lilja, J. J., Neuvonen, M., and Neuvonen, P. J. (2004). Effects of regular consumption of grapefruit juice  
551 on the pharmacokinetics of simvastatin. *British journal of clinical pharmacology* 58, 56–60

- 552 Lohitnavy, M., Lohitnavy, O., Chaijittiprasert, K., Taytiwat, P., and Polnok, S. (2004). Bioequivalence  
553 study of two formulations of simvastatin tablets in healthy Thai volunteers. *Arzneimittelforschung* 54,  
554 31–34
- 555 Lohitnavy, M., Methaneethorn, J., Chiang-Ngernthanyakool, R., Tongpeng, W., Chan-Im, D., and  
556 Phaohorm, S. (2015). Pharmacokinetic model for the inhibition of simvastatin metabolism by  
557 itraconazole. In *2015 37th Annual International Conference of the IEEE Engineering in Medicine and*  
558 *Biology Society (EMBC)* (IEEE), 3246–3249
- 559 Loria, P., Bertolotti, M., Cassinadri, M. T., Dilengite, M. A., Bozzoli, M., Carubbi, F., et al. (1994).  
560 Short-term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects.  
561 *Hepatology* 19, 882–888
- 562 Luo, J., Yang, H., and Song, B.-L. (2019). Mechanisms and regulation of cholesterol homeostasis. *Nature*  
563 *Reviews Molecular Cell Biology* , 1–21
- 564 Magot, T., Malmendier, C., Ouguerram, K., Lontie, J., and Lutton, C. (1991). In vivo effect of simvastatin  
565 on lipoprotein cholesteryl ester metabolism in normocholesterolemic volunteers. *Clinica chimica acta*  
566 196, 59–68
- 567 Marino, M. R., Vachharajani, N. N., and Hadjilambris, O. W. (2000). Irbesartan does not affect the  
568 pharmacokinetics of simvastatin in healthy subjects. *The Journal of Clinical Pharmacology* 40, 875–879
- 569 Mauro, V. F. (1993). Clinical pharmacokinetics and practical applications of simvastatin. *Clinical*  
570 *Pharmacokinetics* doi:10.2165/00003088-199324030-00002
- 571 Methaneethorn, J., Chaiwong, K., Pongpanich, K., Sonsingh, P., and Lohitnavy, M. (2014). A  
572 pharmacokinetic drug-drug interaction model of simvastatin and clarithromycin in humans. In *2014*  
573 *36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society* (IEEE),  
574 5703–5706
- 575 Mol, M., Leuven, J. G., Erkelens, D., Schouten, T., and Stalenhoef, A. (1986). Effects of synvinolin  
576 (MK-733) on plasma lipids in familial hypercholesterolaemia. *The Lancet* 328, 936–939
- 577 Mol, M. J., Erkelens, D. W., Leuven, J. A. G., Schouten, J. A., and Stalenhoef, A. F. (1988). Simvastatin  
578 (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia.  
579 *Atherosclerosis* 69, 131–137
- 580 Mölgaard, J., Von Schenck, H., and Olsson, A. (1988). Effects of simvastatin on plasma lipid, lipoprotein  
581 and apolipoprotein concentrations in hypercholesterolaemia. *European Heart Journal* 9, 541–551
- 582 Moon, A. and Smith, T. (2002). A preliminary evaluation of neural network analysis for pharmacodynamic  
583 modeling of the dosing of the hydroxymethylglutaryl coenzyme A-reductase inhibitors simvastatin and  
584 atorvastatin. *Clinical therapeutics* 24, 653–661
- 585 Mousa, O., Brater, D. C., Sundblad, K. J., and Hall, S. D. (2000). The interaction of diltiazem with  
586 simvastatin. *Clinical Pharmacology & Therapeutics* 67, 267–274
- 587 Neuvonen, P. J., Kantola, T., and Kivistö, K. T. (1998). Simvastatin but not pravastatin is very susceptible  
588 to interaction with the CYP3A4 inhibitor itraconazole. *Clinical Pharmacology & Therapeutics* 63,  
589 332–341
- 590 Nishio, S., Watanabe, H., Kosuge, K., Uchida, S., Hayashi, H., and Ohashi, K. (2005). Interaction between  
591 amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. *Hypertension*  
592 *research* 28, 223–227
- 593 Ntanios, F. J., Jones, P. J., and Frohlich, J. J. (1999). Effect of 3-hydroxy-3-methylglutaryl coenzyme A  
594 reductase inhibitor on sterol absorption in hypercholesterolemic subjects. *Metabolism* 48, 68–73


- 595 Ogungbenro, K., Wagner, J. B., Abdel-Rahman, S., Leeder, J. S., and Galetin, A. (2019). A population  
596 pharmacokinetic model for simvastatin and its metabolites in children and adolescents. *European journal*  
597 *of clinical pharmacology* 75, 1227–1235
- 598 Owens, D., Collins, P., Johnson, A., Tighe, O., Robinson, K., and Tomkin, G. (1991).  
599 Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different  
600 mechanisms. *Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism* 1082, 303–309
- 601 Paalvast, Y., Kuivenhoven, J. A., and Groen, A. K. (2015). Evaluating computational models of cholesterol  
602 metabolism. *Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids* 1851, 1360–  
603 1376
- 604 Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., and Niemi, M. (2006). SLCO1B1 polymorphism markedly  
605 affects the pharmacokinetics of simvastatin acid. *Pharmacogenetics and genomics* 16, 873–879
- 606 Pentikainen, P. J., Saraheimo, M., Schwartz, J. I., Amin, R. D., Schwartz, M. S., Brunner-Ferber, F., et al.  
607 (1992). Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. *The Journal*  
608 *of Clinical Pharmacology* 32, 136–140
- 609 Pietro, D. A., Alexander, S., Mantell, G., Staggers, J. E., Cook, T. J., and Group II, T. S. M. S. (1989).  
610 Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II).  
611 *The American journal of cardiology* 63, 682–686
- 612 Prueksaritanont, T., Vega, J. M., Zhao, J., Gagliano, K., Kuznetsova, O., Musser, B., et al. (2001).  
613 Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. *The Journal of*  
614 *Clinical Pharmacology* 41, 573–581
- 615 Recto, C. S., Acosta, S., and Dobs, A. (2000). Comparison of the efficacy and tolerability of simvastatin  
616 and atorvastatin in the treatment of hypercholesterolemia. *Clinical cardiology* 23, 682–688
- 617 Saito, Y., Yoshida, S., Nakaya, N., Hata, Y., and Goto, Y. (1991). Comparison between morning and evening  
618 doses of simvastatin in hyperlipidemic subjects. a double-blind comparative study. *Arteriosclerosis and*  
619 *Thrombosis: A Journal of Vascular Biology* 11, 816–826
- 620 Simard, C., O'hara, G. E., Prévost, J., Guilbaud, R., Massé, R., and Turgeon, J. (2001). Study of the drug–  
621 drug interaction between simvastatin and cisapride in man. *European journal of clinical pharmacology*  
622 57, 229–234
- 623 Somogyi, E. T., Bouteiller, J.-M., Glazier, J. A., König, M., Medley, J. K., Swat, M. H., et al. (2015).  
624 libroadrunner: a high performance SBML simulation and analysis library. *Bioinformatics* 31, 3315–3321
- 625 Tsamandouras, N., Dickinson, G., Guo, Y., Hall, S., Rostami-Hodjegan, A., Galetin, A., et al. (2014).  
626 Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and  
627 simvastatin acid using a population-modeling approach. *Clinical Pharmacology & Therapeutics* 96,  
628 90–100
- 629 Tsamandouras, N., Dickinson, G., Guo, Y., Hall, S., Rostami-Hodjegan, A., Galetin, A., et al. (2015).  
630 Development and application of a mechanistic pharmacokinetic model for simvastatin and its active  
631 metabolite simvastatin acid using an integrated population PBPK approach. *Pharmaceutical research*  
632 32, 1864–1883
- 633 Tubic-Grozdanis, M., Hilfinger, J. M., Amidon, G. L., Kim, J. S., Kijek, P., Staubach, P., et al. (2008).  
634 Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus  
635 immediate release oral dosage forms. *Pharmaceutical research* 25, 1591–1600
- 636 Tuomilehto, J., Guimaraes, A. C., Kettner, H., Lithell, H., Pitkänen, M., Sailer, D., et al. (1994). Dose-  
637 response of simvastatin in primary hypercholesterolemia. *Journal of cardiovascular pharmacology* 24,  
638 941–949

- 639 Ucar, M., Neuvonen, M., Luurila, H., Dahlqvist, R., Neuvonen, P., and Mjörndal, T. (2004). Carbamazepine  
640 markedly reduces serum concentrations of simvastatin and simvastatin acid. *European journal of clinical*  
641 *pharmacology* 59, 879–882
- 642 Virtanen, P., Gommers, R., Oliphant, T. E., Haberland, M., Reddy, T., Cournapeau, D., et al. (2020).  
643 SciPy 1.0: fundamental algorithms for scientific computing in Python. *Nature Methods* 17, 261–272.  
644 doi:10.1038/s41592-019-0686-2
- 645 Walker, J. F., Pingeon, R. A., and Shapiro, D. A. (1990). Efficacy and tolerability of simvastatin (epistatin)  
646 in the elderly. *Drug Investigation* 2, 53–56
- 647 Welsh, C., Xu, J., Smith, L., König, M., Choi, K., and Sauro, H. M. (2023). libroadrunner 2.0: a high  
648 performance SBML simulation and analysis library. *Bioinformatics* 39, btac770
- 649 Wojtyniak, J.-G., Selzer, D., Schwab, M., and Lehr, T. (2021). Physiologically based precision dosing  
650 approach for drug-drug-gene interactions: A simvastatin network analysis. *Clinical Pharmacology &*  
651 *Therapeutics* 109, 201–211
- 652 Wrona, A., Balbus, J., Hrydziuszko, O., and Kubica, K. (2015). Two-compartment model as a teaching  
653 tool for cholesterol homeostasis. *Advances in physiology education* 39, 372–377
- 654 Zhi, J., Moore, R., Kanitra, L., and Mulligan, T. E. (2003). Effects of orlistat, a lipase inhibitor, on the  
655 pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy  
656 volunteers. *The Journal of Clinical Pharmacology* 43, 428–435
- 657 Zhou, Q., Ruan, Z.-r., Jiang, B., Yuan, H., and Zeng, S. (2013). Simvastatin pharmacokinetics in  
658 healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1  
659 polymorphisms. *Die Pharmazie-An International Journal of Pharmaceutical Sciences* 68, 124–128
- 660 Ziviani, L., Da Ros, L., Squassante, L., Milleri, S., Cugola, M., and Iavarone, L. E. (2001). The effects of  
661 lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. *British journal of*  
662 *clinical pharmacology* 51, 147–152







**Figure 1. Physiologically based model of simvastatin and cholesterol.** **A)** Whole-body model consisting of lung, liver, kidney, gastrointestinal tract and blood compartments. Simvastatin (SV), simvastatin acid (SVA), simvastatin metabolites (SVM), LDL cholesterol (LDL-C) and VLDL cholesterol (VLDL-C) are transported via the systemic circulation. **B)** Liver submodel including simvastatin metabolism, cholesterol synthesis and the LDL receptor (LDLR) pathway. SVA and SVM competitively inhibit HMG-CoA reductase. Cholesterol has a negative feedback on HMG-CoA reductase and HMG-CoA synthase. The LDLR pathway consists of: (1) synthesis of LDLR; (2) transport of LDLR to the membrane; (3) binding of LDL-C to LDLR; (4) internalization of the LDLR-LDL-C complex; (5) recycling of LDLR; and (P) degradation of LDLR. The liver exports cholesterol via VLDL-C particles and SVM into the bile, resulting in the enterohepatic circulation (EHC) of SVM. **C)** Submodel of the gastrointestinal tract including first-pass metabolism of SVM, enterohepatic circulation (EHC), and fecal excretion. SVM can reach the intestine via biliary transport from the liver. SV and SVM can be absorbed into the intestine via enterocytes. Within the enterocytes, SV is converted to SVM by CYP3A4. SV and SVM are transported into the blood. **D)** Kidney submodel consisting of urinary excretion of SVM via the kidneys. Created with BioRender.com.



**Figure 2. Time courses after single application of simvastatin.** Simvastatin model performance on the training data set consisting of a single oral dose of simvastatin. Model predictions for plasma concentrations of simvastatin (black), simvastatin acid (blue), total simvastatin inhibitors (orange), active simvastatin inhibitors (red), and simvastatin plus simvastatin acid (green). Means are shown or mean $\pm$ SD if SD was reported in the study. For the simulation, the oral dose was set according to the dosing protocol in Tab. 1. Data from (Backman et al., 2000; Chung et al., 2006; Gehin et al., 2015; Jacobson, 2004; Jiang et al., 2017; Kantola et al., 1998; Keskitalo et al., 2008, 2009; Kim et al., 2019; Kyrklund et al., 2000; Lilja et al., 2000, 2004; Lohitnavy et al., 2004; Marino et al., 2000; Mousa et al., 2000; Neuvonen et al., 1998; Pasanen et al., 2006; Pentikainen et al., 1992; Tubic-Grozdanis et al., 2008; Ucar et al., 2004; Zhou et al., 2013). Keskitalo2008 was not included in training of the model.




**Figure 3. Time courses after multiple applications of simvastatin.** Simvastatin model performance on validation data consisting of multiple oral dosing of simvastatin. Model predictions for simvastatin (black), simvastatin acid (blue), total simvastatin inhibitors (orange), active simvastatin inhibitors (red), and simvastatin plus simvastatin acid (green) after multiple oral doses of simvastatin. Means are shown or mean $\pm$ SD if SD was reported in the study. For the simulation, oral doses were set according to the dosing protocol in Tab. 1.. Data from (Bergman et al., 2004; Hsyu et al., 2001; Jacobson, 2004; Nishio et al., 2005; Simard et al., 2001; Zhi et al., 2003; Ziviani et al., 2001). Data from Prueksaritanont et al. (2001) was excluded.




**Figure 4. Time course simulation of hypercholesterolemia classes and simvastatin therapy.** The columns correspond to the different classes of hypercholesterolemia. The simulation starts with a baseline reference value of 3 mM LDL-C, corresponding to no changes in the LDLR pathway. At time 0 weeks, the FH parameter is set to either 0.1 or 10, depending on the class, and simulated for 52 weeks, resulting in hypercholesterolemia. After 52 weeks, either 20 mg simvastatin daily for 52 weeks (solid lines) or no therapy (dashed lines) was applied. As a control, the no mutation simulation does not change any FH parameter. For a zoom on the last week, see Fig. S3. **A)** Graphic overview of the hypercholesterolemia subtypes: no mutation in the LDLR pathway; (1) LDLR synthesis; (2) transport of LDLR to the membrane; (3) binding of LDL-C to LDLR; (4) internalization of the LDLR-LDL-C complex; (5) recycling of LDLR; (P) degradation of LDLR; **B)** Plasma concentration of SV and SVA. **C)** Plasma LDL-C. **D)** Hepatic cholesterol. **E)** Overview of the LDLR pool consisting of plasma LDLR, LDLR-LDL-C complex or membrane LDLR. **F)** Fractional LDLR pool. **G)** Rate of processes involved in LDLR turnover: LDLR degradation, LDLR synthesis, LDLR membrane transport, LDLR recycling, LDL-C binding/uptake, LDLR turnover. **H)** LDL-C rates in the liver: LDL-C net export from liver, LDL-C uptake, LDL-C absorption, LDL-C export, cholesterol synthesis. **I)** Plasma LDL-C Rates: LDL-C fecal loss, LDL-C from diet, LDL-C net consumption, VLDL-C to LDL-C conversion.







**Figure 5. Steady-state simulation of hypercholesterolemia classes and simvastatin therapy.** Simulations were performed as shown in Fig. 4 with FH parameters varied in [0.01, 100]. Shown are steady-state values after 52 weeks of either 20 mg simvastatin therapy (circle, solid lines) or no therapy (squares, dashed lines). Values correspond to the mean  $\pm$  SD daily concentration of the last day. Gray areas indicate the range of FH parameter changes that lead to hypercholesterolemia (LDL-C  $\geq$  3.0 mM). **A)** Graphic overview of the hypercholesterolemia subtypes: no mutation in the LDLR pathway; (1) LDLR synthesis; (2) transport of LDLR to the membrane; (3) binding of LDL-C to LDLR; (4) internalization of the LDLR-LDL-C complex; (5) recycling of LDLR; (P) degradation of LDLR; **B)** Plasma concentration of SV and SVA. **C)** Plasma LDL-C. **D)** Hepatic cholesterol. **E)** Overview of the LDLR pool consisting of plasma LDLR, LDLR-LDL-C complex or membrane LDLR. **F)** Fractional LDLR pool. **G)** Rate of processes involved in LDLR turnover: LDLR degradation, LDLR synthesis, LDLR membrane transport, LDLR recycling, LDL-C binding/uptake, LDL-R turnover. **H)** LDL-C rates in the liver: LDL-C net export from liver, LDL-C uptake, LDL-C absorption, LDL-C export, cholesterol synthesis. **I)** Plasma LDL-C Rates: LDL-C fecal loss, LDL-C from diet, LDL-C net consumption, VLDL-C to LDL-C conversion.



**Figure 6. Prediction of LDL-C time course with simvastatin therapy.** Time courses of plasma concentrations of LDL-C after multiple doses of oral simvastatin. For prediction, multiple model simulations were performed according to the different hypercholesterolemia classes using the dosing regimen of each study (see Tab. 2). For a single simulation, the respective FH parameter was adjusted to achieve the reported baseline LDL-C concentration. Simulation curves are the mean of the six FH classes with shaded areas corresponding to the range. The color corresponds to the respective dose of simvastatin. Data are mean or mean  $\pm$  SD when SD was reported. Data from (Crouse 3rd et al., 1999; Davidson et al., 1997; Geiss et al., 2002; Isaacsohn et al., 2003; Jones et al., 1998; Keech et al., 1994; Kosoglou et al., 2002; Loria et al., 1994; Li et al., 2003; Mølgaard et al., 1988; Mol et al., 1986, 1988; Ntanios et al., 1999; Nishio et al., 2005; Owens et al., 1991; Pietro et al., 1989; Recto et al., 2000; Saito et al., 1991; Tuomilehto et al., 1994; Walker et al., 1990).



**Figure 7. Prediction of LDL-C change with simvastatin therapy.** Comparison of predicted and observed LDL-C changes with simvastatin therapy. Simulations and data from Fig. 6. **A)** Observed vs. predicted absolute change in LDL-C. Observed changes are mean  $\pm$  SD, predicted changes are mean across FH classes with errors corresponding to the range. For changes for individual FH classes, see Fig. S4. **B)** Observed absolute changes in LDL-C over time with reference simulations. Observed changes are mean  $\pm$  SD. Simulations were initialized with a baseline plasma LDL-C value of 5.9 mM, which is the mean baseline value across all datasets. Simvastatin doses were applied every 24 h for 52 weeks. Lines are mean values across FH classes and shaded areas are minimum and maximum values across FH classes. **C)** Residuals of absolute observed changes and absolute predicted changes in plasma LDL-C with simvastatin therapy versus time. SD values were calculated using error propagation. **D)** Same as A but for relative changes in LDL-C. **E)** Same as B but for relative changes in LDL-C. **F)** Same as C) but for relative changes in LDL-C. Some studies did not report relative changes, only concentrations. Absolute and relative changes were calculated using the reported baseline LDL-C values. When studies reported only relative changes, absolute changes were calculated from relative changes with baseline values. SD values from relative changes were plotted and converted to SD for absolute changes using the coefficient of variation. For Keech1994, the reported baseline value at -8 weeks was used for time 0 weeks. Data from (Crouse 3rd et al., 1999; Davidson et al., 1997; Geiss et al., 2002; Isaacsohn et al., 2003; Jones et al., 1998; Keech et al., 1994; Kosoglou et al., 2002; Li et al., 2003; Loria et al., 1994; Mølgaard et al., 1988; Mol et al., 1986, 1988; Nishio et al., 2005; Ntanos et al., 1999; Owens et al., 1991; Pietro et al., 1989; Recto et al., 2000; Saito et al., 1991; Tuomilehto et al., 1994; Walker et al., 1990).



**Figure 8. Relative and absolute LDL-C reductions depending on hypercholesterolemia class with simvastatin therapy.** **A)** Graphic overview of the classes of hypercholesterolemia: (1) LDLR synthesis; (2) transport of LDLR to the membrane; (3) binding of LDL-C to LDLR; (4) internalization of the LDLR-LDL-C complex; (5) recycling of LDLR; (P) degradation of LDLR; **B)** Plasma LDL-C concentrations after 52 weeks of simvastatin therapy **C)** Absolute LDL-C reduction with simvastatin therapy versus no therapy. **D)** Relative LDL-C reduction versus no treatment. Gray areas indicate parameter ranges that lead to hypercholesterolemia (LDL-C > 3 mM). Simulation of 52 weeks of daily simvastatin therapy at various doses. Values are averaged from the last day of treatment. FH parameters were modified in [10E-3, 10E3]. The model was simulated for 59 weeks to reach steady state before treatment, followed by 52 weeks of therapy.



**Table 1.** Overview of clinical studies with simvastatin pharmacokinetics.

| Reference                     | PK-DB     | PMID     | Subjects | Dosing Protocol                                                                                   | Metabolites                     | Fit | Validation |
|-------------------------------|-----------|----------|----------|---------------------------------------------------------------------------------------------------|---------------------------------|-----|------------|
| Backman et al. (2000)         | PKDB00345 | 10976543 | 10       | Single dose, po 40 mg SV                                                                          | SV, SVA                         | ✓   |            |
| Bergman et al. (2004)         | PKDB00361 | 15317833 | 12       | Multiple dose, po 10 mg SV, every 24 hrs for 7 days                                               | SV, SVA, aHMG, tHMG             |     | ✓          |
| Chung et al. (2006)           | PKDB00243 | 16580903 | 19       | Single dose, po 40 mg SV                                                                          | SV                              | ✓   |            |
| Gehin et al. (2015)           | PKDB00352 | 25323804 | 22       | Single dose, po 40 mg SV                                                                          | SV, SVA                         | ✓   |            |
| Hsyu et al. (2001)            | PKDB00355 | 11709322 | 31       | Multiple dose, po 20 mg SV, every 24 hrs for 14 days                                              | aHMG                            |     | ✓          |
| Jacobson (2004)               | PKDB00364 | 15518608 | 137      | Study 1: Single dose, po 40 mg SV<br>Study 2: Multiple dose, po SV 40 mg, every 24 hrs for 7 days | Study 1: SV, SVA<br>Study 2: SV | ✓   | ✓          |
| Jiang et al. (2017)           | PKDB00366 | 28350522 | 26       | Single dose, po 40 mg SV                                                                          | SV, SVA                         | ✓   |            |
| Kantola et al. (1998)         | PKDB00350 | 9728898  | 12       | Single dose, po 40 mg SV                                                                          | SV, SVA                         | ✓   |            |
| Keskitalo et al. (2008)       | PKDB00509 | 19238649 | 24       | Single dose, po 20 mg SV                                                                          | SV, SVA                         |     | ✓          |
| Keskitalo et al. (2009)       | PKDB00510 | 19842935 | 32       | Single dose, po 40 mg SV                                                                          | SV, SVA                         | ✓   |            |
| Kim et al. (2019)             | PKDB00353 | 30729119 | 19       | Single dose, po 40 mg SV                                                                          | SV, SVA                         | ✓   |            |
| Kyrklund et al. (2000)        | PKDB00365 | 11180018 | 10       | Single dose, po 40 mg SV                                                                          | SV, SVA                         | ✓   |            |
| Lilja et al. (1998)           | PKDB00342 | 9834039  | 10       | Single dose po, SV 60 mg                                                                          | SV, SVA, aHMG, tHMG             | ✓   |            |
| Lilja et al. (2000)           | PKDB00354 | 11061578 | 10       | Single dose, po 40 mg SV                                                                          | SV, SVA                         | ✓   |            |
| Lilja et al. (2004)           | PKDB00344 | 15206993 | 10       | Single dose, po 40 mg SV                                                                          | SV, SVA                         | ✓   |            |
| Lohitnavy et al. (2004)       | PKDB00346 | 14979606 | 18       | Single dose, po 40 mg SV                                                                          | SV                              | ✓   |            |
| Marino et al. (2000)          | PKDB00360 | 10934672 | 14       | Single dose, po 40 mg SV                                                                          | SV+SVA                          | ✓   |            |
| Mousa et al. (2000)           | PKDB00362 | 10741630 | 10       | Single dose, po 20 mg SV                                                                          | SV                              | ✓   |            |
| Neuvonen et al. (1998)        | PKDB00372 | 9542477  | 20       | Single dose, po 40 mg SV                                                                          | SV+SVA, tHMG                    | ✓   |            |
| Nishio et al. (2005)          | PKDB00514 | 16097365 | 8        | Multiple dose, po 5 mg SV, every 24 hrs for 4 weeks                                               | tHMG                            |     | ✓          |
| Pasanen et al. (2006)         | PKDB00368 | 17108811 | 32       | Single dose, po 40 mg SV                                                                          | SV, SVA                         | ✓   |            |
| Pentikainen et al. (1992)     | PKDB00371 | 1613123  | 12       | Single dose, po 40 mg SV                                                                          | aHMG, tHMG                      | ✓   |            |
| Simard et al. (2001)          | PKDB00358 | 11497338 | 11       | Multiple dose, po 20 mg SV, every 12 hrs for 4 days                                               | SV, SVA                         |     | ✓          |
| Tubic-Grozdanis et al. (2008) | PKDB00343 | 18213452 | 7        | Single dose, po 20 mg SV                                                                          | SV, SVA                         | ✓   |            |
| Ucar et al. (2004)            | PKDB00347 | 14691614 | 12       | Single dose, po 10 mg SV                                                                          | SV, SVA                         | ✓   |            |
| Zhi et al. (2003)             | PKDB00357 | 12723464 | 29       | Multiple dose, po 10 mg SV, every 8 hrs for 13 days                                               | SV, SVA                         |     | ✓          |
| Zhou et al. (2013)            | PKDB00363 | 23469684 | 17       | Single dose, po 40 mg SV                                                                          | SV                              | ✓   |            |
| Ziviani et al. (2001)         | PKDB00348 | 11259986 | 18       | Multiple dose, po 40 mg SV, every 24 hrs for 8 days                                               | SV+SVA                          |     | ✓          |

SV: simvastatin, SVA: simvastatin acid, aHMG: active HMG-CoA reductase inhibitors, tHMG: total HMG-CoA reductase inhibitors, po: oral dose

**Table 2.** Overview of clinical studies with LDL-C measurements in simvastatin therapy.

| Reference                | PK-DB     | PMID     | Subjects       | Duration | Baseline LDL-C [mM]           | Dosing protocol                                                       | Inclusion criteria                                                                                                                                                         |
|--------------------------|-----------|----------|----------------|----------|-------------------------------|-----------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Crouse 3rd et al. (1999) | PKDB00507 | 10335764 | 202/215        | 12 weeks | 5.5/5.5                       | Multiple dose, po 40/80 mg SV, every 12 hrs                           | Patients with hypercholesterolemia patients                                                                                                                                |
| Davidson et al. (1997)   | PKDB00653 | 9024733  | 147/147/147    | 6 weeks  | 5.15/5.15/5.15                | Multiple dose, po 40/80/160 mg SV, every 24 hrs                       | Patients with baseline plasma LDL-C 160-250 mg/dl.                                                                                                                         |
| Geiss et al. (2002)      | PKDB00650 | 12058342 | 9/8            | 4 weeks  | 7.1/4.8                       | Multiple dose, po 13.3/13.8 mg SV, every 24 hrs                       | Patients with heterozygous FH (baseline plasma LDL-C $\geq 5.4$ mM) and type 2 diabetes mellitus and mixed hyperlipoproteinemia (baseline plasma LDL-C $\geq 4.1$ mM)      |
| Isaacsohn et al. (2003)  | PKDB00651 | 12539808 | 47/46/47       | 6 weeks  | 3.28/3.0/3.08                 | Multiple dose, po placebo/20/40/80 mg SV, every 24 hrs                | Patients with baseline plasma LDL-C $\geq 1.9$ mM.                                                                                                                         |
| Jones et al. (1998)      | PKDB00296 | 9514454  | 70/49/61       | 8 weeks  | 3.86/3.87/3.34                | Multiple dose, po 10/20/40 mg SV, every 24 hrs                        | Healthy patients with baseline plasma LDL-C $>4.2$ mM and triglycerides $<4.2$ mM.                                                                                         |
| Keech et al. (1994)      | PKDB00508 | 8005129  | 208            | 3 years  | 4.86                          | Multiple dose, po placebo/20/40 mg SV, every 24 hrs                   | Patients with higher than average risk for CHD and baseline total plasma cholesterol $\geq 3.5$ mM.                                                                        |
| Kosoglou et al. (2002)   | PKDB00376 | 12236852 | 12/8           | 2 weeks  | 4.33/4.08                     | Multiple dose, po 10/20 mg SV, every 24 hrs                           | Healthy subjects with LDL-C $\geq 3.36$ mM.                                                                                                                                |
| Loria et al. (1994)      | PKDB00373 | 8138261  | 5              | 1 day    | 2.51                          | Single dose, po 80 mg SV                                              | No hypercholesterolemia; cholecystectomy.                                                                                                                                  |
| Li et al. (2003)         | PKDB00511 | 14579918 | 21/21          | 12 weeks | 4.27/4.22                     | Multiple dose, po 20 mg SV, every 24 hrs                              | Mixed hypercholesterolemia with LDL-C $\geq 4.2$ mM and triglycerides $<300$ mg/dl.                                                                                        |
| Mølgaard et al. (1988)   | PKDB00512 | 3402470  | 11/10          | 24 weeks | 8.91/5.05                     | Multiple dose, po 20/40 mg SV, every 24 hrs                           | FH type 2 with baseline LDL-C mean $8.87 \pm 0.48$ mM; polygenic hypercholesterolemia.                                                                                     |
| Mol et al. (1986)        | PKDB00513 | 2877129  | 8/4/8/4/7/8    | 4 weeks  | 9.89/8.8/10.47/9.97/8.78/8.72 | Multiple dose, po 2.5/5/10/20/40/80 mg SV, every 24 hrs               | Primary hypercholesterolemia LDL-C with $>6.7$ mM                                                                                                                          |
| Mol et al. (1988)        | PKDB00514 | 3279966  | 10/20/8        | 25 weeks | 10.03/9.39/10.05              | Multiple dose, po 20/40 mg SV, every 24 hrs                           | Heterozygous FH with baseline plasma LDL-C mean $9.70 \pm 1.93$ mM.                                                                                                        |
| Ntanos et al. (1999)     | PKDB00375 | 9920147  | 7/11           | 24 weeks | 7.69/8.12                     | Multiple dose, po 20/40 mg SV, every 24 hrs                           | Hypercholesterolemia with LDL-C $>4.16$ mM; all FH types were excluded.                                                                                                    |
| Nishio et al. (2005)     | PKDB00514 | 16097365 | 8              | 4 weeks  | 4.24                          | Multiple dose, po 5 mg SV, every 24 hrs                               | Mild hypertension and hypercholesterolemia with mean plasma LDL-C $4.24 \pm 0.67$ mM.                                                                                      |
| Owens et al. (1991)      | PKDB00652 | 1903069  | 6/4            | 12 weeks | 5.90/6.44                     | Multiple dose, po placebo/20/40 mg SV, every 24 hrs                   | Hypercholesterolemic with serum cholesterol levels $>6.5$ mM and serum triglycerides $<2$ mM.                                                                              |
| Pietro et al. (1989)     | PKDB00516 | 2646895  | 82/80          | 12 weeks | 6.49/6.49                     | Multiple dose, po 20/40 mg SV, every 24 hrs                           | Primary hypercholesterolemia; Baseline plasma LDL-C $>5.56$ mM or above 4.91 mM with positive family history; separated into FH and non-FH.                                |
| Recto et al. (2000)      | PKDB00517 | 11016019 | 125/124        | 12 weeks | 5.00/5.00                     | Multiple dose, po 20/40 mg SV, every 24 hrs                           | Baseline plasma LDL-C $>3.4$ mM.                                                                                                                                           |
| Saito et al. (1991)      | PKDB00654 | 2065035  | 29/27/32/28    | 12 weeks | 4.8/5.07/5.02/5.28            | Multiple dose, po 2.5/5 mg SV in the morning or evening, every 24 hrs | Patients with hyperlipidemia and serum cholesterol $\geq 220$ mg/dl; 15% of patients with FH                                                                               |
| Tuomilehto et al. (1994) | PKDB00374 | 7898078  | 28/28/27/26/29 | 8 weeks  | 5.1/5.0/5.2/5.2/5.0           | Multiple dose 2.5/5/10/20/40 mg SV every 24 hrs                       | Primary hypercholesterolemia; FH type 1,3,4,5 were excluded; Baseline plasma LDL-C $>4.7$ but $<5.0$ mM.                                                                   |
| Walker et al. (1990)     | PKDB00377 | -        | 32/32/32/32    | 4 weeks  | 5.87/5.88/5.81/5.97           | Multiple dose, po 2.5/5/10/20 mg SV, every 24 hrs                     | Type 2 hyperlipidaemia; with baseline plasma LDL-C $\geq 3.6$ mM; Patients with secondary forms of hyperlipidaemia or types I, III, IV or V hyperlipidaemia were excluded. |

Total number of subjects: 2603 in 53 datasets used for model validation (placebo datasets not included). Number of subjects is count at baseline.  
SV: simvastatin, FH: familial hypercholesterolemia, po: oral dose